Printer Friendly

Varian Oncology Systems Signs Joint Marketing Agreements With Medison America, Inc. For Prostate Brachytherapy, 3D Ultrasound.

PALO ALTO, Calif.--(BW HealthWire)--May 28, 1998--

Firms Will Also Collaborate On Developing Other Image-Guided Products

Varian Oncology Systems today announced the signing of agreements with Medison America, Inc., and its Cone/Medison joint venture, to jointly market certain of the firms' products for applications in radiation oncology, urology, and gynecology.

The primary aim of the agreements, according to the companies, is an enhanced cooperation in the field of prostate brachytherapy utilizing 3D ultrasound, where urologists and radiation oncologists collaborate to treat cancer with permanent or temporary radioactive seed implants.

The products covered under the agreements are Varian's VariSource high dose rate brachytherapy system, the Voluson 530D 3D ultrasound system from Medison America, and the Combison 301 ultrasound system from Cone/Medison.

"The unique three-dimensional capabilities of the Voluson 530D system, together with our treatment planning capabilities for prostate brachytherapy, offer an extraordinary opportunity to extend the quality assurance and efficiency of these procedures," said Varian's David Hall, Ph.D., VariSource product manager. "This combination of technologies is specifically designed to make brachytherapy easier and has the potential to be of considerable benefit to up to 200,000 American males per year."

"Medison's advanced 3D ultrasound technology has the capability of direct digital electronic input for real-time monitoring and optimization of treatment plans," said Peter Klein, president and chief executive officer of Medison America, Inc. "This partnership with Varian, the world leader in radiation therapy products, opens significant new markets for applications of 3D ultrasound in cancer therapy."

The firms said their research collaboration will be focused on developing new applications of the three-dimensional ultrasound technology for other image-guided therapies in the treatment of cancer and other disorders. Varian's efforts in this area will be carried out through a subsidiary, Varian Biosynergy Inc., according to its president, Robert Sutherland, Ph.D.

Varian Oncology Systems and Varian Biosynergy are units of the $500 million Health Care systems business of Varian Associates, Inc.

Varian Associates, Inc., is the world's leading manufacturer of medical linear accelerators and related radiotherapy products for the treatment of cancer. The more than 3,500 Varian systems in service around the world treat over one million patients annually. Varian is also the premier manufacturer of x-ray tubes used in CT scanners and mammography and other medical imaging systems. A diversified, high technology company with annual sales of $1.4 billion, Varian is based in Palo Alto, Calif.

Medison America, Inc. is a world-leading manufacturer of diagnostic ultrasound equipment. Medison's advanced 3D and multi-planar reconstruction ultrasound technology is redefining the use of ultrasound. Medison has operations and R&D facilities in the United States, Europe, and Asia, widespread medical product manufacturing and an installed base of over 45,000 systems. Medison is based in Pleasanton, Calif.

Cone/Medison is a joint venture between Medison America, Inc. and Cone Instruments concentrating on selling Medison's new C301 ultrasound product into the emerging urology market. Cone/Medison is based in Solon, Ohio.

 CONTACT: Varian
 Gary Simpson, 650/424-5782
 gary.simpson@corp.varian.com


COPYRIGHT 1998 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1998, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Article Type:Article
Geographic Code:1USA
Date:May 28, 1998
Words:502
Previous Article:ABAG to Convene Regional Hearing on BofA Merger; Supervisors Mary King and Michael Yaki Make the Request.
Next Article:Xenometrix Receives Extension on Bridge Notes.
Topics:


Related Articles
Medison and MedSim Announce a Strategic Collaboration.
Medison America, Inc. Signs Joint Marketing Agreements With Varian Oncology Systems for Prostate Brachytherapy; Firms Will Also Collaborate On...
New Varian Health Care Unit to Specialize in Brachytherapy Systems for Cancer Care.
Varian Medical Systems, Inc. Acquires Cancer Treatment Planning Systems Division of Multimedia Medical Systems, Inc.
Implant Sciences Partners With MED-TEC, Inc. for Exclusive United States Distribution of Its I-Plant Iodine-125 Brachytherapy Seed for the Treatment...
BC Cancer Agency to Install Advanced Imaging and Radiotherapy System for Cancer Treatment From Varian Medical Systems.
BUSINESS NOTES SYNCOR EXPANDING SERVICES TO BRAZIL.
AREA FIRM GETS FDA APPROVAL ON PROSTATE CANCER THERAPY.
Varian Medical Systems Receives FDA 510'k' Clearance for VariSeed 7.1 Treatment Planning Software for Permanent Seed Implant Brachytherapy.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters